2月23日 - ** 药物开发商ImmunityBio IBRX.O股价盘前上涨1.3%，报8.61美元
** 该公司称其癌症疗法Anktiva在2025年的销售额激增，产品净收入增长了700%，达到1.13亿美元
** Anktiva 获准用于治疗膀胱癌，这是一种细胞异常生长影响膀胱的疾病。
** 公司称，该药物现已在 33 个国家获得批准；沙特阿拉伯也于 1 月份批准 Anktiva 用于肺癌治疗，预计将在两个月内上市
** 2025 年股价下跌 ~23%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.